Lee, Jessica K.
Sivakumar, Smruthy
Schrock, Alexa B.
Madison, Russell
Fabrizio, David
Gjoerup, Ole
Ross, Jeffrey S.
Frampton, Garrett M.
Napalkov, Pavel
Montesion, Meagan
Schutzman, Jennifer L.
Ye, Xin
Hegde, Priti S.
Nagasaka, Misako
Oxnard, Geoffrey R.
Sokol, Ethan S.
Ou, Sai-Hong Ignatius http://orcid.org/0000-0002-1764-4975
Shi, Zhen
Funding for this research was provided by:
Foundation Medicine, Inc.
Article History
Received: 5 May 2022
Accepted: 16 November 2022
First Online: 9 December 2022
Competing interests
: J.K.L., S.S., A.B.S., R.M., D.F., O.G., J.S.R., G.M.F., M.M., G.R.O., P.S.H., and E.S.S. are employees of Foundation Medicine Inc, a wholly owned subsidiary of Roche, and have stock ownership in Roche. J.S.R. is consultant and stock owner in Celsius TX and Tango Tx. S.H.I.O. has received honorarium from Pfizer, Roche/Genentech, Takeda/ARIAD, Astra Zeneca, Daiichi Sankyo, BeiGene, Lilly, Caris Life Sciences Inc, has stock ownership in Turning Point Therapeutics and Elevation Oncology, and has been a member of scientific advisory board for Elevation Oncology. M.N. is on the advisory board for AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly, and Company and Genentech; consultant for Caris Life Sciences (virtual tumor board); speaker for Blueprint Medicines and Takeda; and reports travel support from AnHeart Therapeutics. P.N., J.L.S., X.Y., and Z.S. are employees of Genentech, Inc. and have equity in Roche.